Table 4: Summary of the principal characteristics of the main studies exploring the effects of the treatment with L-thyroxin on the bone mineral density (BMD).

AuthorsThyroid diseaseNumber of patientsType of treatmentLength of treatment (years)Menopausal statusEffect on BMD

Affinito et al., 1996 [12]Hypothyroidism 54SuppressiveVariousAfterDecreased
Baldini et al., 2002 [13]Nontoxic goiter 43Suppressive≥2Before and afterUnchanged
Chen et al., 2004 [14]Cancer (thyroidectomy) 69Suppressive 44 before
25 after
Decreased
Nodular goiter 32NoneNANone
Foldes et al., 1993 [15]Subclinical hyperthyroidism 37NoneNABefore and afterNone
Toxic adenoma 22NoneNADecreased in postmenopausal
Gorres et al., 1996 [16]Cancer (thyroidectomy) 65Suppressive15 before
32 after
18 men
Unchanged
Hadji et al., 2000 [17]Nontoxic goiter and hypothyroidism 156Substitutive>5Before and afterSlightly decreased
Heijckmann et al., 2005 [18]Cancer 59Suppressive>6Unchanged
Kung and Yeung, 1996 [19]Cancer (thyroidectomy) 46Suppressive2AfterDecreased
Larijani et al., 2004 [20]Thyroid nodules 41Substitutive>1BeforeUnchanged
Mikosch et al., 2001 [21]Cancer 98SuppressiveUnchanged
Nuzzo et al., 1998 [22]Nontoxic goiter 40Suppressive1.5–14BeforeUnchanged
Sijanovic and Karner, 2001 [23]Cancer (thyroidectomy) 19Suppressive9BeforeDecreased
Toivonen et al., 1998 [24]Cancer (thyroidectomy) 29Suppressive9–1125 women
4 men
Decreased

NA: not applicable.